Health Care Workers' Preferences in the Delivery of Atrial Fibrillation Screening: A Systematic Review.

Heart Lung CircJul 3, 2026 (epub)
Clinical ResearchCardiology

Ureni Halahakone, Samantha J Borg, Sameera Senanayake et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review examined health care workers' (HCWs) preferences for atrial fibrillation (AF) screening, analyzing 26 studies published from January 2013 to August 2023. The review found that while HCWs generally support electrocardiogram-based screening, preferences regarding implementation and delivery roles vary significantly among different professional groups and settings.

Key findings

  • HCWs support electrocardiogram-based screening tools for AF.
  • Preferences for screening delivery roles and resources vary across professional groups.
  • Two main themes emerged: screening preferences and implementation challenges.

Why it matters

Understanding HCWs' preferences is crucial for developing effective AF screening programs. Aligning these preferences with organizational capabilities can enhance the integration of screening into routine practice, potentially improving patient outcomes.

Source

PubMed · PMID 42392917

Published in Heart Lung Circ. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Cardiology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.